Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility

Trends in Biochemical Sciences

Volumn 27, Issue 11, 2002, Pages 552-558

  Turton, Kathryn ^a   Chaddock, John A ^b   Acharya, K Ravi ^a  

^a University of Bath   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BOTULINUM TOXIN; NEUROTOXIN; NEUROTRANSMITTER; SNARE PROTEIN; TETANUS TOXIN;

AMINO ACID SUBSTITUTION; BOTULISM; CATALYSIS; CHANNEL GATING; CLOSTRIDIUM; CLOSTRIDIUM BARATI; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM TETANI; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DYSPHAGIA; HUMAN; HYPERHIDROSIS; INTERNALIZATION; INTRACELLULAR TRANSPORT; LICENSING; MIGRAINE; MYOFASCIAL PAIN; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STRUCTURE ACTIVITY RELATION; TARGET CELL; TETANUS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM BARATII; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM TETANI;

EID: 0036850282     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(02)02177-1     Document Type: Review

References (63)

1. Eleopra R., et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett. 256:1998;135-138.
2. Lacy D.B., Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291:1999;1091-1104.
3. Kurazono H., et al. Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A. J. Biol. Chem. 267:1992;14721-14729.
4. Lacy D.B., et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:1998;898-902.
5. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:2000;693-699.
6. Umland T.C., et al. Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol. 4:1997;788-792.
7. Sutton J.M., et al. Tyrosine-1290 of tetanus neurotoxin plays a key role in its binding to gangliosides and functional binding to neurones. FEBS Lett. 493:2001;45-49.
8. Ginalski K., et al. Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett. 482:2000;119-124.
9. Fotinou C., et al. The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276:2001;32274-32281.
10. Emsley P., et al. The structures of the HC fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J. Biol. Chem. 275:2000;8889-8894.
11. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 11:1986;314-317.
12. Li L., Singh B.R. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J. Nat. Toxins. 7:1998;215-226.
13. Nishiki T., et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378:1996;253-257.
14. Nishiki T., et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269:1994;10498-10503.
15. Munro P., et al. High sensitivity of mouse neuronal cells to tetanus toxin requires a GPI-anchored protein. Biochem. Biophys. Res. Commun. 289:2001;623-629.
16. Montecucco C., et al. Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett. 346:1994;92-98.
17. Blaustein R.O., et al. The N-terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Lett. 226:1987;115-120.
18. Sheridan R.E. Gating and permeability of ion channels produced by botulinum toxin types A and E in PC12 cell membranes. Toxicon. 36:1998;703-717.
19. Bajjalieh S.M. Synaptic vesicle docking and fusion. Curr. Opin. Neurobiol. 9:1999;321-328.
20. Humeau Y., et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 82:2000;427-446.
21. Meunier F.A., et al. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J. Physiol. Paris. 96:2002;105-113.
22. Curtis D.R., De Groat W.C. Tetanus toxin and spinal inhibition. Brain Res. 10:1968;208-212.
23. Pellizzari R., et al. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:1999;259-268.
24. Halpern J.L., Neale E.A. Neurospecific binding, internalization, and retrograde axonal transport. Curr. Top. Microbiol. Immunol. 195:1995;221-241.
25. Herreros J., et al. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem. J. 347:2000;199-204.
26. Donovan J.J., Middlebrook J.L. Ion-conducting channels produced by botulinum toxin in planar lipid membranes. Biochemistry. 25:1986;2872-2876.
27. Li L., Singh B.R. Spectroscopic analysis of pH-induced changes in the molecular features of type A botulinum neurotoxin light chain. Biochemistry. 39:2000;6466-6474.
28. Ferrer-Montiel A.V., et al. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J. Biol. Chem. 271:1996;18322-18325.
29. Encinar J.A., et al. Structural stabilization of botulinum neurotoxins by tyrosine phosphorylation. FEBS Lett. 429:1998;78-82.
30. Martinez-Arca S., et al. Clostridial neurotoxin-insensitive vesicular SNAREs in exocytosis and endocytosis. Biol. Cell. 92:2000;449-453.
31. Vaidyanathan V.V., et al. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 72:1999;327-337.
32. Pellizzari R., et al. Structural determinants of the specificity for synaptic vesicle-associated membrane protein/synaptobrevin of tetanus and botulinum type B and G neurotoxins. J. Biol. Chem. 271:1996;20353-20358.
33. Washbourne P., et al. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett. 418:1997;1-5.
34. Rossetto O., et al. SNARE motif and neurotoxin. Nature. 372:1994;415-416.
35. Hanson M.A., Stevens R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution. Nat. Struct. Biol. 7:2000;687-692.
36. De Filippis V., et al. Structural studies on the zinc-endopeptidase light chain of tetanus neurotoxin. Eur. J. Biochem. 229:1995;61-69.
37. Fu F.N., et al. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry. 37:1998;5267-5278.
38. Li L., Singh B.R. Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry. 39:2000;10581-10586.
39. Simpson L.L., et al. The role of zinc binding in the biological activity of botulinum toxin. J. Biol. Chem. 276:2001;27034-27041.
40. Tonello F., et al. Metal substitution of tetanus neurotoxin. Biochem. J. 322:1997;507-510.
41. Rigoni M., et al. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 288:2001;1231-1237.
42. Matthews B.W. Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 21:1988;333-340.
43. Li L., et al. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry. 39:2000;2399-2405.
44. Zhou L., et al. Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry. 34:1995;15175-15181.
45. Rossetto O., et al. Active-site mutagenesis of tetanus neurotoxin implicates TYR-375 and GLU-271 in metalloproteolytic activity. Toxicon. 39:2001;1151-1159.
46. Binz T., et al. Arg362 and Tyr365 of the botulinum neurotoxin type A light chain are involved in transition state stabilization. Biochemistry. 41:2002;1717-1723.
47. Ossig R., et al. Exocytosis requires asymmetry in the central layer of the SNARE complex. EMBO J. 19:2000;6000-6010.
48. Hayashi T., et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J. 13:1994;5051-5061.
49. Keller J.E., Neale E.A. The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. 276:2001;13476-13482.
50. Johnson E.A. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53:1999;551-575.
51. Munchau A., Bhatia K.P. Uses of botulinum toxin injection in medicine today. BMJ. 320:2000;161-165.
52. Heckmann M., et al. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N. Engl. J. Med. 344:2001;488-493.
53. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 85:2000;101-105.
54. Silberstein S., et al. Botulinum toxin type A as a migraine preventive treatment. Headache. 40:2000;445-450.
55. Eleopra R., et al. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci. Lett. 224:1997;91-94.
56. Chaddock J.A., et al. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors. 18:2000;147-155.
57. Chaddock J.A., et al. Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 68:2000;2587-2593.
58. Simpson L.L. Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie. 82:2000;943-953.
59. Knight A., et al. Non-viral neuronal gene delivery mediated by the HC fragment of tetanus toxin. Eur. J. Biochem. 259:1999;762-769.
60. Figueiredo D.M., et al. Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport. Exp. Neurol. 145:1997;546-554.
61. Zdanovskaia M.V., et al. Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules. J. Protein Chem. 19:2000;699-707.
62. Lambin P., et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe. 4:1998;183-188.
63. Minton N.P., et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol. Rev. 17:1995;357-364.